{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:14:56Z","timestamp":1760908496477},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T00:00:00Z","timestamp":1240963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00280-009-1011-z","type":"journal-article","created":{"date-parts":[[2009,4,28]],"date-time":"2009-04-28T09:57:23Z","timestamp":1240912643000},"page":"113-120","source":"Crossref","is-referenced-by-count":18,"title":["A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer"],"prefix":"10.1007","volume":"65","author":[{"given":"Junji","family":"Furuse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Ohkawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitaka","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yamao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taketo","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,29]]},"reference":[{"key":"1011_CR1","first-page":"82","volume-title":"TNM classification of malignant tumours. Liver, UICC","year":"2002","unstructured":"Sobin LH, Wittekind CH (eds) (2002) TNM classification of malignant tumours. Liver, UICC, 6th edn. Wiley-Liss, New York, pp 82\u201383","edition":"6"},{"key":"1011_CR2","unstructured":"National Cancer Center. Cancer statistics in Japan 2007. http:\/\/www.fpcr.or.jp\/publication\/statistics.html . Accessed 10 March, 2008"},{"key":"1011_CR3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sjoden PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593\u2013600","journal-title":"Ann Oncol"},{"key":"1011_CR4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0959-8049(97)10166-6","volume":"34","author":"M Hejna","year":"1998","unstructured":"Hejna M, Pruckmayer M, Raderer M (1998) The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34:977\u2013986","journal-title":"Eur J Cancer"},{"key":"1011_CR5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","volume":"54","author":"G Falkson","year":"1984","unstructured":"Falkson G, MacIntyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54:965\u2013969","journal-title":"Cancer"},{"key":"1011_CR6","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.1996.14.8.2311","volume":"14","author":"YZ Patt","year":"1996","unstructured":"Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I et al (1996) Phase II trial of intravenous fluorouracil and subcutaneous interferon alpha-2b for biliary tract cancer. J Clin Oncol 14:2311\u20132315","journal-title":"J Clin Oncol"},{"key":"1011_CR7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1984.2.11.1245","volume":"2","author":"JH Harvey","year":"1984","unstructured":"Harvey JH, Smith FP, Schein PS (1984) 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 2:1245\u20131248","journal-title":"J Clin Oncol"},{"key":"1011_CR8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/0959-8049(95)00323-B","volume":"31A","author":"PA Ellis","year":"1995","unstructured":"Ellis PA, Norman A, Hill A et al (1995) Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31A:1594\u20131598","journal-title":"Eur J Cancer"},{"key":"1011_CR9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000070310","volume":"64","author":"C Morizane","year":"2003","unstructured":"Morizane C, Okada S, Okusaka T, Ueno H, Saisho T (2003) Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology 64:475\u2013476","journal-title":"Oncology"},{"key":"1011_CR10","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.bjc.6602576","volume":"92","author":"S Rao","year":"2005","unstructured":"Rao S, Cunningham D, Hawkins RE et al (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 92:1650\u20131654","journal-title":"Br J Cancer"},{"key":"1011_CR11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008352123009","volume":"12","author":"M Penz","year":"2001","unstructured":"Penz M, Kornek GV, Raderer M et al (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183\u2013186","journal-title":"Ann Oncol"},{"key":"1011_CR12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","volume":"22","author":"N Tsavaris","year":"2004","unstructured":"Tsavaris N, Kosmas C, Gouveris P et al (2004) Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 22:193\u2013198","journal-title":"Invest New Drugs"},{"key":"1011_CR13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-005-0095-3","volume":"57","author":"T Okusaka","year":"2006","unstructured":"Okusaka T, Ishii H, Funakoshi A et al (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57:647\u2013653","journal-title":"Cancer Chemother Pharmacol"},{"key":"1011_CR14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.bjc.6601796","volume":"90","author":"C Hsu","year":"2004","unstructured":"Hsu C, Shen YC, Yang CH et al (2004) Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil\/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 90:1715\u20131719","journal-title":"Br J Cancer"},{"key":"1011_CR15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cncr.20753","volume":"103","author":"SR Alberts","year":"2005","unstructured":"Alberts SR, Al-Khatib H, Mahoney MR et al (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103:111\u2013118","journal-title":"Cancer"},{"key":"1011_CR16","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","volume":"23","author":"JJ Knox","year":"2005","unstructured":"Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332\u20132338","journal-title":"J Clin Oncol"},{"key":"1011_CR17","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/cncr.21591","volume":"104","author":"JY Cho","year":"2005","unstructured":"Cho JY, Paik YH, Chang YS et al (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced\/metastatic biliary tract carcinoma. Cancer 104:2753\u20132758","journal-title":"Cancer"},{"key":"1011_CR18","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/sj.bjc.6601736","volume":"90","author":"DC Doval","year":"2004","unstructured":"Doval DC, Sekhon JS, Gupta SK et al (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90:1516\u20131520","journal-title":"Br J Cancer"},{"key":"1011_CR19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/annonc\/mdi046","volume":"16","author":"S Thongprasert","year":"2005","unstructured":"Thongprasert S, Napapan S, Charoentum C et al (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16:279\u2013281","journal-title":"Ann Oncol"},{"key":"1011_CR20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andre","year":"2004","unstructured":"Andre T, Tournigand C, Rosmorduc O et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339\u20131343","journal-title":"Ann Oncol"},{"key":"1011_CR21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1016209901417","volume":"20","author":"R Kuhn","year":"2002","unstructured":"Kuhn R, Hribaschek A, Eichelmann K et al (2002) Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 20:351\u2013356","journal-title":"Invest New Drugs"},{"key":"1011_CR22","doi-asserted-by":"crossref","first-page":"217s","DOI":"10.1200\/JCO.2006.08.0481","volume":"25","author":"RR McWilliams","year":"2007","unstructured":"McWilliams RR, Foster NR, Quevedo FJ et al (2007) NCCTG phase I\/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: phase II results. J Clin Oncol, Proc Am Soc Clin Oncol 25:217s (abstr 4578)","journal-title":"J Clin Oncol, Proc Am Soc Clin Oncol"},{"key":"1011_CR23","first-page":"763","volume":"69","author":"S Fujii","year":"1978","unstructured":"Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Jpn J Cancer Res (Gann) 69:763\u2013772","journal-title":"Jpn J Cancer Res (Gann)"},{"key":"1011_CR24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/00001813-199609000-00002","volume":"7","author":"R Pazdur","year":"1996","unstructured":"Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho DH (1996) Phase I trials of uracil-tegafur (UFT) using 5 and 28\u00a0day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs 7:728\u2013733","journal-title":"Anticancer Drugs"},{"key":"1011_CR25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jjco\/hyl075","volume":"36","author":"J Furuse","year":"2006","unstructured":"Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H et al (2006) Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol 36:552\u2013556","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"1011_CR26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62(5):849\u2013855","journal-title":"Cancer Chemother Pharmacol"},{"key":"1011_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1011_CR28","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"F Eckel","year":"2007","unstructured":"Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896\u2013902","journal-title":"Br J Cancer"},{"key":"1011_CR29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00534-007-1280-z","volume":"15","author":"J Furuse","year":"2008","unstructured":"Furuse J, Takada T, Miyazaki M et al (2008) Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 15:55\u201362","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"1011_CR30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/jjco\/hym116","volume":"37","author":"N Yonemoto","year":"2007","unstructured":"Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T (2007) A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37:843\u2013851","journal-title":"Jpn J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1011-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1011-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1011-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:58Z","timestamp":1559038018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1011-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1011-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,29]]}}}